STRO

In the past six months, Sutro Biopharma's stock (STRO) experienced significant fluctuations, with its share price increasing by 72.34% to $15.34 as of September 18, 2026, from $8.90 on September 22, 2025, and reaching a 52-week high of $43.85 and a low of $7.15. Key events included a 1-for-10 reverse stock split in December 2025 to regain Nasdaq compliance, the deprioritization of STRO-002 in March 2026 following a Grade 5 febrile neutropenia event, and an organizational restructuring that reduced the workforce by approximately one-third to extend its cash runway. William Newell departed as CEO and was replaced by Jane Chung. The company published its Q1 2026 earnings report on May 14, 2026, and Q2 2026 financial results on August 12, 2026, which also provided an early update on the STRO-004 Phase 1 study. Promising preclinical data across its pipeline were presented at AACR 2026 on April 19, 2026. Lucas Donigian was appointed as Senior Vice President, Business Development on September 28, 2026. Additionally, the company received a $10 million milestone payment in Q2 2026 for an Astellas-partnered dual-payload immunostimulatory ADC program entering the clinic, and a $7.5 million milestone for a second partnered program reaching IND-enabling toxicology.